Case Study: Commercial Distribution
Transition from Early Access to Commercial Supply in the UK
Market Access. Treatment Continuity.
The Challenge
A US rare disease company with a European affiliate had gained EMA approval for a treatment for a rare cardiovascular disease. Following Brexit, the company received MHRA approval and gained reimbursement for the product in the UK, but had not established a legal entity, nor had a wholesale distribution authorisation, in the UK. The company needed a distribution partner with the infrastructure in the UK to support with its commercial launch.
Our Approach
Prior to MHRA approval of the treatment, Tanner Pharma had been supporting the company on an early access program in the UK. Post-approval, Tanner procured product intended for the UK market from the company’s European affiliate, managed the importation of EU QP-certified batches into the UK, and completed the applicable RPi import checks before distribution to public and private hospitals across the UK. Tanner managed all invoicing and cash collection activities with customers and provided reliable distribution services to complement the company’s commercial activities.
